Importer of Controlled Substances Application: Fresenius Kabi USA, LLC, 79950-79951 [2024-22450]
Download as PDF
<![CDATA[
79950
Federal Register / Vol. 89, No. 190 / Tuesday, October 1, 2024 / Notices
produced in each Subject Country, and
such merchandise from other countries.
(13) (OPTIONAL) A statement of
whether you agree with the above
definitions of the Domestic Like Product
and Domestic Industry; if you disagree
with either or both of these definitions,
please explain why and provide
alternative definitions.
Authority: This proceeding is being
conducted under authority of Title VII
of the Tariff Act of 1930; this notice is
published pursuant to § 207.61 of the
Commission’s rules.
By order of the Commission.
Issued: September 25, 2024.
Lisa Barton,
Secretary to the Commission.
[FR Doc. 2024–22441 Filed 9–30–24; 8:45 am]
BILLING CODE 7020–02–P
The Drug Enforcement
Administration requires that all
comments be submitted electronically
through the Federal eRulemaking Portal,
which provides the ability to type short
comments directly into the comment
field on the web page or attach a file for
lengthier comments. Please go to
https://www.regulations.gov and follow
the online instructions at that site for
submitting comments. Upon submission
of your comment, you will receive a
Comment Tracking Number. Please be
aware that submitted comments are not
instantaneously available for public
view on https://www.regulations.gov. If
you have received a Comment Tracking
Number, your comment has been
successfully submitted and there is no
need to resubmit the same comment.
SUPPLEMENTARY INFORMATION: In
accordance with 21 CFR 1301.33(a), this
is notice that on August 22, 2024, Curia
Wisconsin, Inc., 870 Badger Circle,
Grafton, Wisconsin 53024–0000,
applied to be registered as a bulk
manufacturer of the following basic
class(es) of controlled substance(s):
ADDRESSES:
DEPARTMENT OF JUSTICE
Drug Enforcement Administration
[Docket No. DEA–1434]
Bulk Manufacturer of Controlled
Substances Application: Curia
Wisconsin, Inc.
Drug Enforcement
Administration, Justice.
ACTION: Notice of application.
AGENCY:
Curia Wisconsin, Inc., has
applied to be registered as a bulk
manufacturer of basic class(es) of
controlled substance(s). Refer to
Supplementary Information listed below
for further drug information.
DATES: Registered bulk manufacturers of
the affected basic class(es), and
applicants, therefore, may submit
electronic comments on or objections to
the issuance of the proposed registration
on or before December 2, 2024. Such
persons may also file a written request
for a hearing on the application on or
before December 2, 2024.
SUMMARY:
Controlled substance
Drug code
khammond on DSKJM1Z7X2PROD with NOTICES
Lysergic acid diethylamide .....................................................................................................................................................
Tetrahydrocannabinols ...........................................................................................................................................................
4-Bromo-2,5-dimethoxyphenethylamine .................................................................................................................................
3,4-Methylenedioxyamphetamine ...........................................................................................................................................
3,4-Methylenedioxymethamphetamine ...................................................................................................................................
5-Methoxy-N-N-dimethyltryptamine ........................................................................................................................................
Dimethyltryptamine .................................................................................................................................................................
Psilocybin ...............................................................................................................................................................................
Psilocyn ..................................................................................................................................................................................
Lisdexamfetamine ..................................................................................................................................................................
Methylphenidate .....................................................................................................................................................................
Amobarbital ............................................................................................................................................................................
Nabilone .................................................................................................................................................................................
4-Anilino-N-Phenethyl-4-Piperidine (ANPP) ...........................................................................................................................
Opium extracts .......................................................................................................................................................................
Opium, powdered ...................................................................................................................................................................
Opium, granulated ..................................................................................................................................................................
Opium poppy ..........................................................................................................................................................................
Noroxymorphone ....................................................................................................................................................................
Fentanyl ..................................................................................................................................................................................
The company plans to bulk
manufacture the listed controlled
substances for the purpose of analytical
reference standards or for sale to its
customers. In reference to the drug code
7370 (Tetrahydrocannabinols), the
company plans to bulk manufacture as
synthetic. No other activities for these
drug codes are authorized for this
registration.
DEPARTMENT OF JUSTICE
Marsha L. Ikner,
Acting Deputy Assistant Administrator.
ACTION:
[FR Doc. 2024–22446 Filed 9–30–24; 8:45 am]
BILLING CODE 4410–09–P
VerDate Sep<11>2014
17:42 Sep 30, 2024
Jkt 265001
[Docket No. DEA–1435]
Importer of Controlled Substances
Application: Fresenius Kabi USA, LLC
Drug Enforcement
Administration, Justice.
AGENCY:
Notice of application.
Registered bulk manufacturers of
the affected basic class(es), and
applicants, therefore, may submit
electronic comments on or objections to
the issuance of the proposed registration
on or before October 31, 2024. Such
persons may also file a written request
for a hearing on the application on or
before October 31, 2024.
DATES:
The Drug Enforcement
Administration requires that all
comments be submitted electronically
through the Federal eRulemaking Portal,
which provides the ability to type short
ADDRESSES:
Fresenius Kabi USA, LLC has
applied to be registered as an importer
of basic class(es) of controlled
substance(s). Refer to Supplementary
PO 00000
Frm 00066
Fmt 4703
Sfmt 4703
I
I
I
I
I
I
I
I
I
II
II
II
II
II
II
II
II
II
II
II
Information listed below for further
drug information.
Drug Enforcement Administration
SUMMARY:
7315
7370
7392
7400
7405
7431
7435
7437
7438
1205
1724
2125
7379
8333
9610
9639
9640
9650
9668
9801
Schedule
E:\FR\FM\01OCN1.SGM
01OCN1
Federal Register / Vol. 89, No. 190 / Tuesday, October 1, 2024 / Notices
comments directly into the comment
field on the web page or attach a file for
lengthier comments. Please go to
https://www.regulations.gov and follow
the online instructions at that site for
submitting comments. Upon submission
of your comment, you will receive a
Comment Tracking Number. Please be
aware that submitted comments are not
instantaneously available for public
view on https://www.regulations.gov. If
you have received a Comment Tracking
Number, your comment has been
successfully submitted and there is no
need to resubmit the same comment. All
requests for a hearing must be sent to:
(1) Drug Enforcement Administration,
Attn: Hearing Clerk/OALJ, 8701
Morrissette Drive, Springfield, Virginia
22152; and (2) Drug Enforcement
Administration, Attn: DEA Federal
Register Representative/DPW, 8701
Morrissette Drive, Springfield, Virginia
22152. All requests for a hearing should
also be sent to: Drug Enforcement
Administration, Attn: Administrator,
8701 Morrissette Drive, Springfield,
Virginia 22152.
In
accordance with 21 CFR 1301.34(a), this
is notice that on August 12, 2024,
Fresenius Kabi USA, LLC, 3159 Staley
Road, Grand Island, New York 14072–
2028, applied to be registered as an
importer of the following basic class(es)
of controlled substance(s):
SUPPLEMENTARY INFORMATION:
Controlled substance
Drug
code
Schedule
Remifentanil ..................
9739
II
khammond on DSKJM1Z7X2PROD with NOTICES
The company plans to import the
listed controlled substance(s) as bulk
active pharmaceutical ingredient to
manufacture Food and Drug
Administration (FDA)-approved dosage
forms. No other activity for this drug
code is authorized for this registration.
Approval of permit applications will
occur only when the registrant’s
business activity is consistent with what
is authorized under 21 U.S.C. 952(a)(2).
Authorization will not extend to the
import of FDA-approved or nonapproved finished dosage forms for
commercial sale.
Marsha L. Ikner,
Acting Deputy Assistant Administrator.
[FR Doc. 2024–22450 Filed 9–30–24; 8:45 am]
BILLING CODE P
VerDate Sep<11>2014
17:42 Sep 30, 2024
Jkt 265001
permitting electronic submission of
responses.
DEPARTMENT OF JUSTICE
[OMB Number 1121–0329]
Agency Information Collection
Activities; Proposed eCollection
eComments Requested; Extension of a
Previously Approved Collection; State
Criminal Alien Assistance Program
(SCAAP)
Bureau of Justice Assistance,
Department of Justice.
ACTION: 60-Day notice.
AGENCY:
The Bureau of Justice
Assistance, Department of Justice (DOJ),
will be submitting the following
information collection request to the
Office of Management and Budget
(OMB) for review and approval in
accordance with the Paperwork
Reduction Act of 1995.
DATES: Comments are encouraged and
will be accepted for 60 days until
December 2, 2024.
FOR FURTHER INFORMATION CONTACT: If
you have additional comments
especially on the estimated public
burden or associated response time,
suggestions, or need a copy of the
proposed information collection
instrument with instructions or
additional information, please contact
Joseph Husted, State Policy Advisor,
Bureau of Justice Assistance,
Department of Justice, 999 N Capitol St.
NE, Washington, DC 20002; email:
SCAAP@usdoj.gov; telephone: 202–598–
3617.
SUPPLEMENTARY INFORMATION: Written
comments and suggestions from the
public and affected agencies concerning
the proposed collection of information
are encouraged. Your comments should
address one or more of the following
four points:
—Evaluate whether the proposed
collection of information is necessary
for the proper performance of the
functions of the Bureau of Justice
Assistance, including whether the
information will have practical utility;
—Evaluate the accuracy of the agency’s
estimate of the burden of the
proposed collection of information,
including the validity of the
methodology and assumptions used;
—Evaluate whether and if so how the
quality, utility, and clarity of the
information to be collected can be
enhanced; and
—Minimize the burden of the collection
of information on those who are to
respond, including through the use of
appropriate automated, electronic,
mechanical, or other technological
collection techniques or other forms
of information technology, e.g.,
SUMMARY:
PO 00000
Frm 00067
Fmt 4703
Sfmt 4703
79951
Abstract: In response to the Violent
Crime Control and Law Enforcement
Act of 1994, section 130002(b), as
amended in 1996, BJA administers the
State Criminal Alien Assistance
Program (SCAAP) and the Department
of Homeland Security (DHS).
SCAAP provides federal payments to
States and localities that incurred
correctional officer salary costs for
incarcerating undocumented criminal
aliens with at least one felony or two
misdemeanor convictions for violations
of state or local law, and who are
incarcerated for at least 4 consecutive
days during the designated reporting
period and for the following
correctional purposes;
Salaries for corrections officers
Overtime costs
Performance based bonuses
Corrections work force recruitment and
retention
Construction of corrections facilities
Training/education for offenders
Training for corrections officers related
to offender population management
Consultants involved with offender
population
Medical and mental health services
Vehicle rental/purchase for transport of
offenders
Prison Industries
Pre-release/reentry programs
Technology involving offender
management/inter agency information
sharing
Disaster preparedness continuity of
operations for corrections facilities
Overview of This Information
Collection
1. Type of Information Collection:
Extension.
2. The Title of the Form/Collection:
State Criminal Alien Assistance
Program (SCAAP) (Authorizing
Legislation: Section 241(i) of the
Immigration and Nationality Act (8
U.S.C. 1231(i)).
3. The agency form number, if any,
and the applicable component of the
Department sponsoring the collection:
The application process is managed
through the internet, using the Office of
Justice Programs’ (OJP) SCAAP online
application system at: https://
bja.ojp.gov/program/state-criminalalien-assistance-program-scaap/
overview?Program_ID=86.
4. Affected public who will be asked
or required to respond, as well as the
obligation to respond: Affected Public:
State, local and tribal governments. The
obligation to respond is required to
obtain/retain a benefit.
E:\FR\FM\01OCN1.SGM
01OCN1
]]>Agencies
[Federal Register Volume 89, Number 190 (Tuesday, October 1, 2024)]
[Notices]
[Pages 79950-79951]
From the Federal Register Online via the Government Publishing Office [www.gpo.gov]
[FR Doc No: 2024-22450]
-----------------------------------------------------------------------
DEPARTMENT OF JUSTICE
Drug Enforcement Administration
[Docket No. DEA-1435]
Importer of Controlled Substances Application: Fresenius Kabi
USA, LLC
AGENCY: Drug Enforcement Administration, Justice.
ACTION: Notice of application.
-----------------------------------------------------------------------
SUMMARY: Fresenius Kabi USA, LLC has applied to be registered as an
importer of basic class(es) of controlled substance(s). Refer to
Supplementary Information listed below for further drug information.
DATES: Registered bulk manufacturers of the affected basic class(es),
and applicants, therefore, may submit electronic comments on or
objections to the issuance of the proposed registration on or before
October 31, 2024. Such persons may also file a written request for a
hearing on the application on or before October 31, 2024.
ADDRESSES: The Drug Enforcement Administration requires that all
comments be submitted electronically through the Federal eRulemaking
Portal, which provides the ability to type short
[[Page 79951]]
comments directly into the comment field on the web page or attach a
file for lengthier comments. Please go to https://www.regulations.gov
and follow the online instructions at that site for submitting
comments. Upon submission of your comment, you will receive a Comment
Tracking Number. Please be aware that submitted comments are not
instantaneously available for public view on https://www.regulations.gov. If you have received a Comment Tracking Number,
your comment has been successfully submitted and there is no need to
resubmit the same comment. All requests for a hearing must be sent to:
(1) Drug Enforcement Administration, Attn: Hearing Clerk/OALJ, 8701
Morrissette Drive, Springfield, Virginia 22152; and (2) Drug
Enforcement Administration, Attn: DEA Federal Register Representative/
DPW, 8701 Morrissette Drive, Springfield, Virginia 22152. All requests
for a hearing should also be sent to: Drug Enforcement Administration,
Attn: Administrator, 8701 Morrissette Drive, Springfield, Virginia
22152.
SUPPLEMENTARY INFORMATION: In accordance with 21 CFR 1301.34(a), this
is notice that on August 12, 2024, Fresenius Kabi USA, LLC, 3159 Staley
Road, Grand Island, New York 14072-2028, applied to be registered as an
importer of the following basic class(es) of controlled substance(s):
------------------------------------------------------------------------
Drug
Controlled substance code Schedule
------------------------------------------------------------------------
Remifentanil.......................... 9739 II
------------------------------------------------------------------------
The company plans to import the listed controlled substance(s) as
bulk active pharmaceutical ingredient to manufacture Food and Drug
Administration (FDA)-approved dosage forms. No other activity for this
drug code is authorized for this registration.
Approval of permit applications will occur only when the
registrant's business activity is consistent with what is authorized
under 21 U.S.C. 952(a)(2). Authorization will not extend to the import
of FDA-approved or non-approved finished dosage forms for commercial
sale.
Marsha L. Ikner,
Acting Deputy Assistant Administrator.
[FR Doc. 2024-22450 Filed 9-30-24; 8:45 am]
BILLING CODE P
